Vertex Pharmaceuticals (VRTX) has drawn attention with its first-in-class treatment JOURNAVX™ (suzetrigine) for adults with moderate-to-severe acute pain and its FDA approval that has seen their stock surge by 5.3%. Meanwhile, the company has observed a series of stock buy-ins and sell-offs by various investment companies. Interestingly, there have been shares acquired by prominent international entities such as Mirae Asset Global Investments Co. Ltd. and China Universal Asset Management Co. Ltd.. Furthermore, the stock received an 'Outperform' rating from William Blair and an 'Overweight' rating from Cantor Fitzgerald. Notably, the company's stock experienced a lift of 3.2%, taking five-year gains to 83%. However, setbacks in clinical trials have led to a slide in Vertex's share price. The company has remained in the spotlight, with their FDA-approved non-opioid painkiller hailed as a revolutionary, safer alternative to addictive opioids. There are speculations about potential price hikes, despite tempered expectations for JOURNAVX in pain and mixed drug study results. Analysts at Scotiabank expect the price target to rise to $433 from $430 for Vertex Pharmaceuticals.
Vertex Pharmaceuticals VRTX News Analytics from Mon, 23 Sep 2024 07:00:00 GMT to Sat, 08 Feb 2025 13:24:13 GMT -
Rating 5
- Innovation 4
- Information 8
- Rumor -2
